SCIENCE SOURCED WORLDWIDE
LianBio collaborates with world class partners, selecting programs with strong scientific basis and clinical data resulting in a broad and validated late-stage pipeline with first-in-class profile as well as other high potential candidates
Global Clinical Trials Status
Oncology
Phase 1
Phase 2
Phase 3/Pivotal
NBTXR3
Head and Neck Cancer
Solid tumor IO combinations
Infigratinib (BGJ398)
First-line Cholangiocarcinoma (1LCCA)
Second-line Cholangiocarcinoma (2LCCA)*
Gastric Cancer and Other FGFR-Driven Tumors
*LianBio will pursue approval in ex-China LianBio Territories via CPP (i.e. clinical trial waivers with regulatory submission post US FDA approval).
BBP-398
SHP2 Inhibitor for RTK Cancers
Ophthalmology
Phase 1
Phase 2
Phase 3/Pivotal
TP-03
Demodex blepharitis
Meibomian gland disease
Inflammatory Disease
Phase 1
Phase 2
Phase 3/Pivotal
Omilancor
Ulcerative Colitis
Crohn’s Disease
NX-13
Ulcerative Colitis
Crohn’s Disease
LYR-210
Chronic Rhinosinusitis (CRS)
